Doctor's DEA License Yanked for Illegal Prescribing Post-License Loss
Published Date: 5/7/2025
Notice
Summary
Dr. Peter Dashkoff from Arizona had his DEA registration suspended because he wrote controlled substance prescriptions when he wasn’t allowed to practice medicine. After reviewing the case, the DEA decided to revoke his registration to keep the public safe. This means Dr. Dashkoff can no longer legally prescribe certain medications, affecting his medical practice and patients immediately.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
DEA Revokes Doctor’s Controlled‑Substance License
The DEA revoked Peter Dashkoff, M.D.'s DEA Certificate of Registration No. FD3660304, effective June 6, 2025, so he can no longer legally prescribe controlled substances. The Order also denies any pending applications to renew or modify his registration and any other pending application for additional registration in the State of Arizona. The record shows he issued four controlled‑substance prescriptions (two morphine Schedule II and two lorazepam Schedule IV) after his Arizona authority lapsed on June 26, 2024.
DEA Action Intended to Deter Prescribing Violations
The Agency explained it revoked the registration in part to deter similar conduct by other registrants and to protect the public from diversion of controlled substances. The decision states the sanction is meant to "send a message to all registrants" that prescribing without state authority is taken seriously.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Previous / Next Documents
Previous: 2025-07932, Agency Collection Activities; Requesting Comments on Form 5316
The IRS wants your thoughts on Form 5316, which helps groups apply for special tax rules. This is a chance for anyone affected—like trusts and their managers—to suggest ways to make the form easier and less time-consuming. Comments are open now, so jump in before the deadline to help shape the process and possibly save time and hassle!
Next: 2025-07934, Margaret Dennis, D.M.D.; Default Decision and Order
Dr. Margaret Dennis from Jacksonville, FL, lost her DEA license because she prescribed controlled drugs without proper medical reasons and ignored warning signs for over 11 years. Since she didn’t ask for a hearing, her license is officially revoked to protect public safety. This means she can’t legally prescribe these drugs anymore, effective immediately.